125 related articles for article (PubMed ID: 7816323)
1. Chemically-diverse ligands at the glycine B site coupled to N-methyl-D-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice.
Millan MJ; Seguin L
Neurosci Lett; 1994 Aug; 178(1):139-43. PubMed ID: 7816323
[TBL] [Abstract][Full Text] [Related]
2. Blockade of NMDA receptors in the nucleus accumbens elicits spontaneous tail-flicks in rats.
Millan MJ; Audinot V; Honoré P; Bervoets K; Veiga S; Brocco M
Eur J Pharmacol; 2000 Jan; 388(1):37-47. PubMed ID: 10657545
[TBL] [Abstract][Full Text] [Related]
3. Anti-convulsant and adverse effects of the glycineB receptor ligands, D-cycloserine and L-701,324: comparison with competitive and non-competitive N-methyl-D-aspartate receptor antagonists.
Wlaź P
Brain Res Bull; 1998 Aug; 46(6):535-40. PubMed ID: 9744291
[TBL] [Abstract][Full Text] [Related]
4. Intrathecally administered D-cycloserine produces nociceptive behavior through the activation of N-methyl-D-aspartate receptor ion-channel complex acting on the glycine recognition site.
Tan-No K; Esashi A; Nakagawasai O; Niijima F; Furuta S; Sato T; Satoh S; Yasuhara H; Tadano T
J Pharmacol Sci; 2007 May; 104(1):39-45. PubMed ID: 17452810
[TBL] [Abstract][Full Text] [Related]
5. Antinociceptive profiles of non-peptidergic neurokinin1 and neurokinin2 receptor antagonists: a comparison to other classes of antinociceptive agent.
Seguin L; Le Marouille-Girardon S; Millan MJ
Pain; 1995 May; 61(2):325-343. PubMed ID: 7659444
[TBL] [Abstract][Full Text] [Related]
6. Effect of the glycine/NMDA receptor partial agonist, D-cycloserine, on seizure threshold and some pharmacodynamic effects of MK-801 in mice.
Wlaź P; Baran H; Löscher W
Eur J Pharmacol; 1994 May; 257(3):217-25. PubMed ID: 8088343
[TBL] [Abstract][Full Text] [Related]
7. The anticonvulsant and behavioural profile of L-687,414, a partial agonist acting at the glycine modulatory site on the N-methyl-D-aspartate (NMDA) receptor complex.
Tricklebank MD; Bristow LJ; Hutson PH; Leeson PD; Rowley M; Saywell K; Singh L; Tattersall FD; Thorn L; Williams BJ
Br J Pharmacol; 1994 Nov; 113(3):729-36. PubMed ID: 7858861
[TBL] [Abstract][Full Text] [Related]
8. Anticonvulsant effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)-HA-966 in amygdala-kindled rats.
Löscher W; Wlaź P; Rundfeldt C; Baran H; Hönack D
Br J Pharmacol; 1994 May; 112(1):97-106. PubMed ID: 8032669
[TBL] [Abstract][Full Text] [Related]
9. The utility of excitatory amino acid (EAA) antagonists as analgesic agents. II. Assessment of the antinociceptive activity of combinations of competitive and non-competitive NMDA antagonists with agents acting at allosteric-glycine and polyamine receptor sites.
Coderre TJ; Van Empel I
Pain; 1994 Dec; 59(3):353-359. PubMed ID: 7708409
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of NMDA and AMPA antagonists on the locomotor activity induced by selective D1 and D2 dopamine agonists in reserpine-treated mice.
Starr MS; Starr BS
Psychopharmacology (Berl); 1994 Apr; 114(3):469-76. PubMed ID: 7855205
[TBL] [Abstract][Full Text] [Related]
11. Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex.
Bristow LJ; Hutson PH; Kulagowski JJ; Leeson PD; Matheson S; Murray F; Rathbone D; Saywell KL; Thorn L; Watt AP; Tricklebank MD
J Pharmacol Exp Ther; 1996 Nov; 279(2):492-501. PubMed ID: 8930150
[TBL] [Abstract][Full Text] [Related]
12. (+)-HA 966, a partial agonist at the glycine site coupled to NMDA receptors, blocks formalin-induced pain in mice.
Millan MJ; Seguin L
Eur J Pharmacol; 1993 Jul; 238(2-3):445-7. PubMed ID: 8405116
[TBL] [Abstract][Full Text] [Related]
13. Anticonvulsant effects of eliprodil alone or combined with the glycineB receptor antagonist L-701,324 or the competitive NMDA antagonist CGP 40116 in the amygdala kindling model in rats.
Wlaź P; Ebert U; Löscher W
Neuropharmacology; 1999 Feb; 38(2):243-51. PubMed ID: 10218865
[TBL] [Abstract][Full Text] [Related]
14. LU 73068, a new non-NMDA and glycine/NMDA receptor antagonist: pharmacological characterization and comparison with NBQX and L-701,324 in the kindling model of epilepsy.
Potschka H; Löscher W; Wlaź P; Behl B; Hofmann HP; Treiber HJ; Szabo L
Br J Pharmacol; 1998 Nov; 125(6):1258-66. PubMed ID: 9863655
[TBL] [Abstract][Full Text] [Related]
15. Failure of glycine site NMDA receptor antagonists to protect against L-2-chloropropionic acid-induced neurotoxicity highlights the uniqueness of cerebellar NMDA receptors.
Widdowson PS; Gyte AJ; Upton R; Wyatt I
Brain Res; 1996 Nov; 738(2):236-42. PubMed ID: 8955518
[TBL] [Abstract][Full Text] [Related]
16. L-687,414, a low efficacy NMDA receptor glycine site partial agonist in vitro, does not prevent hippocampal LTP in vivo at plasma levels known to be neuroprotective.
Priestley T; Marshall GR; Hill RG; Kemp JA
Br J Pharmacol; 1998 Aug; 124(8):1767-73. PubMed ID: 9756395
[TBL] [Abstract][Full Text] [Related]
17. The glycine/NMDA receptor partial agonist D-cycloserine blocks kainate-induced seizures in rats. Comparison with MK-801 and diazepam.
Baran H; Löscher W; Mevissen M
Brain Res; 1994 Aug; 652(2):195-200. PubMed ID: 7953730
[TBL] [Abstract][Full Text] [Related]
18. NMDA/glutamate mechanism of magnesium-induced anxiolytic-like behavior in mice.
Poleszak E; Wlaź P; Wróbel A; Fidecka S; Nowak G
Pharmacol Rep; 2008; 60(5):655-63. PubMed ID: 19066411
[TBL] [Abstract][Full Text] [Related]
19. Competitive NMDA antagonists enhance the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
Kinoshita H; Hasegawa T; Kameyama T; Yamamoto I; Nabeshima T
Neurosci Lett; 1994 Jun; 174(1):101-4. PubMed ID: 7970141
[TBL] [Abstract][Full Text] [Related]
20. NMDA receptor antagonists acting at the glycineB site in rat models for antipsychotic-like activity.
Karcz-Kubicha M; Wedzony K; Zajaczkowski W; Danysz W
J Neural Transm (Vienna); 1999; 106(11-12):1189-204. PubMed ID: 10651113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
